Stockscreener 앱 받기
14.54
0.41%
-0.06
시간 외 거래:
14.54
전일 마감가:
$14.60
열려 있는:
$14.5
하루 거래량:
49,162
Relative Volume:
0.51
시가총액:
$2.48B
수익:
$420.26M
순이익/손실:
$-41.97M
주가수익비율:
-58.16
EPS:
-0.25
순현금흐름:
$-65.34M
1주 성능:
-1.76%
1개월 성능:
+23.12%
6개월 성능:
-19.00%
1년 성능:
-25.32%
1일 변동 폭
$14.18
$14.84
1주일 범위
$14.18
$15.52
52주 변동 폭
$11.51
$21.92
Hutchmed China Limited Adr Stock (HCM) Company Profile
명칭
Hutchmed China Limited Adr
전화
-
주소
-
HCM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HCM
Hutchmed China Limited Adr
|
14.54 | 2.48B | 420.26M | -41.97M | -65.34M | -0.25 |
|
ZTS
Zoetis Inc
|
161.69 | 69.43B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.27 | 47.30B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.57 | 46.56B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.07 | 20.71B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
308.00 | 13.25B | 2.76B | 1.11B | 898.10M | 22.77 |
Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-24 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-05-04 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-09-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-08-03 | 개시 | Jefferies | Buy |
| 2020-10-02 | 개시 | Deutsche Bank | Buy |
| 2020-03-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-02-20 | 개시 | Goldman | Buy |
| 2019-11-19 | 개시 | CLSA | Buy |
| 2019-10-23 | 재확인 | BofA/Merrill | Buy |
| 2019-07-05 | 개시 | Macquarie | Outperform |
모두보기
Hutchmed China Limited Adr 주식(HCM)의 최신 뉴스
UPDATEInternational companies to host live webcasts at - GlobeNewswire
International companies to host live webcasts at Deutsche - GlobeNewswire
HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial - Barchart.com
Marshall Wace LLP Acquires New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - The AM Reporter
RCSHutchmed China LtdHUTCHMEDData to be Presented at AACR 2025 - TradingView
HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China - Yahoo Finance
HUTCHMEDOncology portfolio growth expected to continue - Research Tree
HUTCHMED (China) Limited (NASDAQ:HCM) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - Defense World
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma - GlobeNewswire Inc.
Intended Retirement of Independent Non-executive Directors and changes of composition of board committees - GlobeNewswire
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 - GlobeNewswire
Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China - The Manila Times
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 - GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023 - AsiaOne
HUTCHMED (HCM) Upgraded to Buy: Here's Why - Yahoo Finance
Wall Street Analysts Believe HUTCHMED (HCM) Could Rally 72.83%: Here's is How to Trade - Yahoo Finance
CN NMPA Guides Pharmas, Research Institutes to Enlarge R&D of Innovative Drugs, High-Quality Generic Drugs - AASTOCKS.com
ABC Arbitrage SA Buys New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - MarketBeat
Sea Limited Sponsored ADR (SE) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Crossmark Global Holdings Inc. Increases Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
CN Healthcare Fund Breaks even w/ Slim Surplus in 2024 - AASTOCKS.com
HUTCHMED Announces NMPA Full Approval for - GlobeNewswire
UBS Trims HUTCHMED (00013.HK)TP to $38.7 w/ Rating Buy - AASTOCKS.com
Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week - Yahoo Finance
HSBC Global Research Prefers BeiGene/ SINO BIOPHARM/ HYGEIA HEALTH Given Higher Visibility in CN Pharma & Medical Device Subsectors - AASTOCKS.com
Hutchmed announces progress, hits milestone with lung cancer treatment - ShareCast
Market news - Research the market
Savolitinib Plus Osimertinib Receives Priority Review in China for Pretreated EGFR+ NSCLC With a MET Amplification - OncLive
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy - The Manila Times
HUTCHMED Announces NDA Acceptance in China with Priority - GlobeNewswire
Jane Street Group LLC Raises Stock Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
HUTCHMED (China) Limited (NASDAQ:HCM) Shares Purchased by State Street Corp - Defense World
HCMHUTCHMED (China) Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy - The Manila Times
HUTCHMED Announces Breakthrough Therapy Designation in - GlobeNewswire
Hutchmed endometrial cancer treatment gets conditional approval in China - ShareCast
Why Alibaba Group Holding Limited (BABA) Is One of the Best ADR Stocks to Invest in? - Yahoo Finance
M&G Plc Has $5.35 Million Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - MarketBeat
How Trump and Harris plan to address housing affordability - Yahoo Finance
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® - GlobeNewswire
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful - The Bakersfield Californian
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial - Yahoo Finance
HUTCHMED (China) Ltd (HCM) (Q2 2024) Earnings Call Highlights: Strong US Sales Propel Growth ... - Yahoo Finance
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - Yahoo Finance
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda - Yahoo Finance
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 - Yahoo Finance
HUTCHMED Voluntarily Withdraws Supplemental New Drug Application in China for Fruquintinib - AASTOCKS.com
Dr Mehta on the Sequencing of CAR T-Cell Therapy and Bispecific Antibodies in Lymphoma - OncLive
What Starbucks' new CEO must instantly do to address crisis - Yahoo Finance
CMBI Raises HUTCHMED (00013.HK) TP to $35.61; Fruquintinib's Overseas Sales Beat - AASTOCKS.com
Hutchmed China Limited Adr (HCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
0.06%
자본화:
|
볼륨(24시간):